Samsung Biologics Signs Letter of Intent for $441.8 Billion Contract Manufacturing Agreement with U.S. Pharmaceutical Company
[Asia Economy Reporter Minwoo Lee] Samsung Biologics announced on the 10th that it signed a letter of intent for a contract to manufacture biopharmaceuticals on consignment worth 441.8 billion KRW with a US-based pharmaceutical company on the 9th.
Hot Picks Today
At President Lee's Call to "Give Enough to Shock," Whistleblower Rewards Become a Real Lottery
- If They Fail Next Year, Bonus Drops to 97 Million Won... A Closer Look at Samsung Electronics DS Division’s 600M vs 460M vs 160M Performance Bonuses
- Lived as Family for Over 30 Years... Daughter-in-Law Cast Aside After Husband's Death
- "If Both Spouses Work There, How Much Would They Make?" "They Earn More Than Me, and I'm a Doctor"... Envy Erupts Over Samsung Electronics' Bonus
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
